https://www.psychologytoday.com/us/...nsequences-blaming-others-how-we-manage-angerFauci wasn't learning, he was LYING. Try to keep up.
https://www.psychologytoday.com/us/...nsequences-blaming-others-how-we-manage-angerFauci wasn't learning, he was LYING. Try to keep up.
Better advice doesn't exist.Listen to the Dr.
You didn't need to be much of an MD to figure that one out.Fauci is very happy he was wrong about Covid-19 possibly over whelming 3rd world countries. BBC did an interesting report with five reasons why it's not (yet) too bad in Africa.
https://www.bbc.com/news/world-africa-54418613
5. Conclusion
Chloroquine, hydroxychloroquine, ferroquine, desethylamodiaquine, mefloquine, pyronaridine and quinine showed in vitro antiviral effective activity against SARS-CoV-2 with IC50 and IC90 compatible with drug oral uptake at doses commonly administered in malaria treatment. These in vitro activities are higher than those obtained with drugs which are evaluated in clinical trials worldwide like remdisivir (23 μM), lopinavir (26.6 μM) or ritonavir (>100 μM) [66]. However, these results must be taken with caution regarding the potential use of antimalarial drugs in SARS-CoV-2 infected patients: it is difficult to translate in vitro study results to actual clinical treatment in patients. Experts agree on the in vitro activity of chloroquine or hydroxychloroquine against SARS-CoV-2 but disagree on hydroxychloroquine efficacy in COVID-19 treatment, which remains controversial [67,68]. In vivo evaluation in animal experimental models is now required to confirm the antiviral effects of these antimalarial drugs on SARS-CoV-2. The antiviral effects of some antimalarial drugs could partially explain the later emergence and spread of COVID-19 pandemic in Africa. It could be necessary now to compare the antimalarial use and the dynamics of COVID-19 country by country to confirm the potential effects of antimalarial drugs. Based on our results, we would expect that countries which commonly use artesunate-amodiaquine or artesunate-mefloquine report fewer cases and deaths than those using artemether-lumefantrine or dihydroartemisinin-piperaquine.
In part, though, some of those views are hard to fight because of the reality that many people have no symptoms, and most of those who do get sick recover quickly. And treatment advances mean that those who become seriously ill are less likely to die from the virus than when it first emerged in the spring. Even though cases and the death toll are rising, infectious disease experts note that death rates appear to be falling.
Like most people, Jay Stibbe, 52, of Fargo, North Dakota, said he and his family are respectful of COVID-19 protocols and wear masks where required. However, Stibbe said he doesn’t see enough “concrete information” about the virus to stop him from going about his normal life, even though North Dakota leads the nation in the number of virus cases per capita.
Hasn't it been clear from the beginning last spring that elderly and those with comorbidities need to be protected? In fact, while I advocate mask wearing, it is possible that only the vulnerable should be avoiding infection and we've made the pandemic worse by delaying herd immunity.She finds it particularly appalling when she sees older people, who are at high risk, shopping at a grocery store without one.
People are looking for reasonable explanations for Africa and age related cases world-wide. Age is at least a 90% factor in death and serious complications from current data. Things like MMR or antimalarial drugs might be factors in older 50+ populations.@nsaspook Thanks for the links to Dr. Campbell, I've been watching his videos every day. I thought the explanation for Africa is that basically no one lives long enough to become old and vulnerable to Covid19, perhaps I missed something. He also seems to have put a fork into hydroxychloroquine as prophylactic and treatment. I accept that conclusion but recall originally HCQ was part of a cocktail and the studies he referenced didn't seem to address that (possibly except zinc).
From the AP link:
Hasn't it been clear from the beginning last spring that elderly and those with comorbidities need to be protected? In fact, while I advocate mask wearing, it is possible that only the vulnerable should be avoiding infection and we've made the pandemic worse by delaying herd immunity.
The striking feature of COVID-19 is that it has a disproportionate impact on the elderly population, yet
the paediatric populations in many reports escape with mild, if any, symptoms[Ferguson et al., 2020].
This is peculiar in a viral illness, as one would assume that the collective immunity accumulated over
a lifetime would arm elderly populations with better defences than their progeny. A study by the
Centers for Disease Control and Prevention (CDC) found that children are most likely and people 65
and older least likely to get sick from influenza. Median incidence values (or attack rate) by age group
were 9.3% for children 0-17 years, 8.8% for adults 18-64 years, and 3.9% for adults 65 years and older
[Tokars et al., 2018]. A simple answer to why COVID-19 is different could be that the elderly population
do not have the physiological reserve or regeneration capacity to fight such a severe burden of
disease. However, more intriguingly, the vaccination history of the individual patient might contribute
to the severity of the disease
Who would have guessed that age is a factor in death? Africa has young population. It is one of the continents where nature still prevails.People are looking for reasonable explanations for Africa and age related cases world-wide. Age is at least a 90% factor in death and serious complications from current data. Things like MMR or antimalarial drugs might be factors in older 50+ populations.
https://www.medrxiv.org/content/10.1101/2020.04.10.20053207v1.full.pdf
With no good understanding of the settings through which the virus is probably to be transmitted, a number of European countries have been forced to reintroduce indiscriminate lockdowns this autumn.
France, Germany, the United Kingdom. and different nations in latest weeks once more shut all eating places and bars, cinemas, theaters and in some situations nonessential outlets to stop well being techniques from collapsing beneath a flood of sufferers. U.S. states from New York to Utah additionally imposed new restrictions as each day new infections within the U.S. are hitting data.
Extrapulmonary manifestations of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are now widely recognized and have important clinical implications.1,2 To our knowledge, the association of SARS-CoV-2 with the respiratory muscles has not been studied. This is surprising, as the respiratory muscles drive alveolar ventilation and their weakness results in acute respiratory failure. In critically ill patients undergoing ventilation, respiratory muscle weakness prolongs mechanical ventilation and increases mortality.3 The aim of this study was to investigate the association of severe coronavirus disease 2019 (COVID-19) with the respiratory muscles in critically ill patients and compare the findings with those obtained from non-COVID-19 critically ill patients.
There is broader agreement — although by no means universal — that schools themselves are not locations with a lot of COVID-19 spread. But this doesn’t mean there is no possibility of spread, and there is little agreement on what is an acceptable level of risk.
https://www.biorxiv.org/content/10.1101/2020.11.15.383323v1.full.pdfHow long might immunity to the coronavirus last? Years, maybe even decades, according to a new study — the most hopeful answer yet to a question that has shadowed plans for widespread vaccination.
Eight months after infection, most people who have recovered still have enough immune cells to fend off the virus and prevent illness, the new data show. A slow rate of decline in the short term suggests, happily, that these cells may persist in the body for a very, very long time to come.
The research, published online, has not been peer-reviewed nor published in a scientific journal. But it is the most comprehensive and long-ranging study of immune memory to the coronavirus to date.
“That amount of memory would likely prevent the vast majority of people from getting hospitalized disease, severe disease, for many years,” said Shane Crotty, a virologist at the La Jolla Institute of Immunology who co-led the new study.
Notably, memory B cells specific for spike or RBD were detected in almost all COVID-19 cases,
with no apparent half-life at 5+ months post-infection. B cell memory to some other infections has been
observed to be long-lived, including 60+ years after smallpox vaccination (58), or 90+ years after
infection with influenza (59), another respiratory virus like SARS-CoV-2.
Ominous! What sad state of affairs...